





Introduction. BRAF exon 15 mutations are the most common molecular 
alterations found in Papillary Thyroid Carcinoma (PTC). The molecular 
profile of PTC has been thoroughly investigated. However, to date, there is 
no information regarding the BRAF molecular profile of the non-neoplastic 
tissue surrounding PTCs. Exploring the molecular signature of non-
malignant tissue may help to better understand thyroid tumorigenesis and 
the events that lead potential precursor lesions to evolve towards carcinoma.  
It has long been speculated that some thyroid nodules may eventually 
progress to thyroid carcinoma. Although the molecular profile of these 
nodules with the potential to progress to carcinoma is still undefined, pre-
operative molecular analysis helps to identify those nodules that are 
neoplastic, with either a RAS-like (TCGA 2014) or a BRAF-like (TCGA 
2014) profile, and that need therefore to be excised. The definition of 
molecular panels can be very useful to inform treatment, to identify the best 
surgical approach in case excision of the nodule is necessary, and to stratify 
patient risk in case a malignant diagnosis (carcinoma) is established by 
histologic examination. 
Aim 1 of this project is to establish whether BRAF mutations are present in 
non-malignant tissue surrounding PTC, and in case they are found to 
characterize their activity in vitro. 
Aim 2 of this project is to set up a RNA based expression panel that may 
provide diagnostic, predictive and prognostic information on thyroid 
nodules/neoplasms. 
 
Material and Methods. Aim 1: we screened the BRAF exon 15 molecular 
status in 30 PTCs and in 100 samples of non-malignant tissue surrounding 
the tumor, using a Next Generation Sequencing platform. BRAF mutations 
were identified (see Results). Therefore, expression vectors for the BRAF-
G593D, BRAF-A598T, BRAF-S607F and BRAF-S607P mutants were 
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generated. Their kinase activity was evaluated measuring the activation of 
the MAPK pathway. This activity was then compared to that of BRAF-WT, 
BRAF-V600E and BRAF-K601E proteins. 
Aim 2: we designed a RNA-based expression panel to detect fusion and to 
identify dysregulated expression of genes known to be altered in thyroid 
cancer, and with the potential for diagnostic and clinical relevance. We 
analyzed a set of 44 fresh-frozen (FF) samples. Fourty-one FF specimens 
included normal thyroid tissue, non-malignant tissue (Hyperplasia and 
Follicular adenoma) and the most common types of thyroid carcinoma: 
PTC-classical variant, PTC-tall cell variant, PTC-follicular variant, 
Follicular thyroid carcinoma, Hürthle cell carcinoma, Anaplastic thyroid 
carcinoma and Medullary thyroid carcinoma. Three specimens of 
Colorectal cancer were analyzed as gene expression controls. 
 
Results. Aim 1: ten of 30 (33.3%) PTC analyzed were BRAF-WT, while 20 
were BRAF-positive (66.6%). In 9 of 100 samples (9.0%) of non-malignant 
tissue surrounding the PTC we identified “uncommon” BRAF mutations, 
including p.G593D, p.A598T, p.S607F and p.S607P. The kinase activity of 
BRAF-G593D, BRAF-A598T, BRAF-S607F and BRAF-S607P were 
evaluated: BRAF-S607F and BRAF-S607P had the same kinase activity of 
the BRAF-WT protein; the BRAF-A598T and BRAF-G593D proteins 
showed decreased kinase activity. All “uncommon” BRAF mutations had a 
lower kinase activity if compared to BRAF-V600E or BRAF-K601E. 
Aim 2: the samples with the BRAF p.V600E mutation had dysregulated 
expression of those genes that characterize the BRAF-like molecular profile 
present in our RNA based panel. Similarly, the samples with RAS mutations 
had dysregulated expression of those genes that characterize the RAS-like 
profile present in our panel. Samples with BRAF p.V600E had 
overexpression of our panel genes with a role in cell proliferation. 
Unsupervised hierarchical analysis of the expression profile identified three 
major clusters in our samples: i) non-malignant tissue; ii) malignant tissue; 
iii) non-follicular thyroid cell derived cancers. 
Conclusion. Aim 1: non-malignant tissue surrounding the thyroid tumor 
may harbor “uncommon” BRAF mutations. However, these mutations do 
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not significantly affect the kinase activity of the altered BRAF protein. Our 
findings indicate that BRAF mutations happen randomly in thyroid 
follicular cells. These “uncommon” BRAF mutants however, do not possess 
the tumorigenic potential necessary for the development of PTC. 
Aim 2: our panel was designed to detect fusion and to identify dysregulated 
expression of genes known to be altered in thyroid cancer. We show that the 
panel identifies three main profiles corresponding to: i) non-malignant 
tissue; ii) malignant tissue; iii) non-follicular thyroid cell derived cancers. 
This novel RNA based panel may be very useful to complement the 







1 The thyroid gland ...............................................................................1 
1.1 Embryology and anatomy ............................................................1 
1.2 Physiology ..................................................................................1 
2 Thyroid neoplasia ...............................................................................3 
2.1 Benign and Borderline Neoplasm .................................................4 
2.2 Papillary Thyroid Carcinoma (PTC) .............................................4 
3.3 Follicular Thyroid Carcinoma (FTC) ............................................6 
3.4 Oncocytic (Hürthle cell) Carcinoma .............................................7 
2.5 Poorly-Differentiated Thyroid Carcinoma (PDTC) .......................7 
2.6 Anaplastic Thyroid Carcinoma (ATC) ..........................................8 
3 Principal molecular alterations in follicular cell-derived neoplasm .......8 
3.1 TSH receptor/cAMP pathway ......................................................9 
3.2 Mitogen-activated protein kinase pathway .................................. 11 
3.2.1 Tyrosine Kinase Receptors.................................................. 12 
 3.2.1.1    RET  ……………………………………………………. 13 
 3.2.1.2    NTRK …………………………………………………... 14 
 3.2.1.3    ALK ……………………………………………………. 16 
3.2.2 BRAF................................................................................. 17 
3.2.3 RAS ................................................................................... 19 
3.3 PI3K/PTEN/AKT pathway ........................................................ 20 
3.4 PPARγ  rearrangement............................................................... 22 
 
Aims of the study ...………………………………………………….….  27 
 
Material and Methods…………………………………………….…….. 28 
1 Next Generation Sequencing………………………………………… 28 
1.1 Cases selection .......................................................................... 28 
1.2 Detection of BRAF mutations .................................................... 29 
1.2.1 DNA extraction and quantification ...................................... 29 
1.2.2 Amplicon library preparation .............................................. 29 
v 
 
1.2.3 Library purification and quantification ................................ 31 
1.2.4 Amplicons dilution, pooling and EmulsionPCR ................... 31 
1.2.5 Recovery and enrichment .................................................... 32 
2 Site-direct mutagenesis and cell trasfection ....................................... 33 
2.1 Mutant BRAF plasmids generation via site-directed mutagenesis 33 
2.2 Cell transfection ........................................................................ 35 
3 Western blot ..................................................................................... 35 
4 Gene panel design ............................................................................ 37 
5 Selection of cases ............................................................................. 38 
6 Next Generation Sequencing ............................................................. 39 
6.1 DNA and RNA extraction .......................................................... 39 
6.2 Retrotransciption and Next Generation Sequencing Protocol ....... 39 
7 Statistical analysis ............................................................................ 41 
 
Results ..………………………………………………….…...………….. 42 
1 Next Generation Sequencing ............................................................. 42 
1.1 Thyroid neoplasia molecular profile ........................................... 42 
1.2 Non-malignant thyroid tissue molecular profile .......................... 42 
2 Functional characterization of BRAF mutations ................................. 48 
2.1 Selection of mutant to test .......................................................... 48 
2.2 Functional characterization ........................................................ 49 
3 Gene panel results………………………………………………… 51 
 
Discussion ……………………………………………….…...………….. 54 
 
References ……………………………………………….…...………….. 59 
 












ATC: anaplastic thyroid carcinoma 
CNS: central nervous system 
CRC: colorectal cancer 
EFVPTC: noninvasive encapsulated follicular variant of papillary thyroid     
carcinoma 
FA: follicular adenoma 
FA-ONC: oncocytic follicular adenoma 
FF: fresh-frozen 
FFPE: formalin-fixed paraffin-embedded 
FNA: fine-needle aspiration 
FTC: follicular thyroid carcinoma 
HYP: hyperplasia 
HTA: hyperfunctioning thyroid carcinoma 
MAPK: mitogen-activated protein kinase 
MAPKKK: mitogen-activated protein kinase kinase kinase 
MIT: mono-iodotyrosine 
MOC: malignant oncocytic carcinoma 
MTC: medullary thyroid carcinoma 
NIFTP: noninvasive follicular thyroid neoplasm with papillary-like nuclear 
features   
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NORM: normal tissue  
NSCLC: non-small cell lung carcinoma 
PDTC: poorly-differentiated thyroid carcinoma 
PTC: papillary thyroid carcinoma 
PTC-CL: papillary thyroid carcinoma classical variant 
PTC-FV: papillary thyroid carcinoma follicular variant 
PTC-TC: papillary thyroid carcinoma tall cell variant 
PsB: psammoma body 
RTK: receptor tyrosine kinase 
TSH: thyroid-stimulating hormone 
TSHR: TSH receptor 
WDT-UMP: well-differentiated tumor of uncertain malignant potential 






1 THE THYROID GLAND 
1.1 EMBRYOLOGY AND ANATOMY 
The word for the thyroid gland derives from the Greek thyreoeidos, with the 
meaning of “shield gland” (thyreos – shield; eidos – form). It is the first 
endocrine organ that develops from the endoderm during the third week of 
gestation until the eleventh week. The thyroid originates from foramen 
cecum, an invagination in the floor of the pharynx, that undergoes 
enlargement, difurcation, lobulation and detachment from the pharynx. Its 
development results in a butterfly-shaped gland located at the base of the 
neck, and it consists of two lateral lobes united by the isthmus, a thin band 
of connective tissue (Figure 1.A).  
In a healthy adult, a normal thyroid gland weighs 15-25 g, and each lobe is 
about 4 cm in length and 15-20 mm in width, with a thickness of 20-39 
mmm. It is important to notice that these parameters are very variable, 
especially they could be altered due to any disease. 
The gland’s principal histological architecture is the follicle, a single layer 
of epithelial cells, called thyroid follicular cells, which is filled with colloid 
(Figure 1.B). In between the follicles another subtype of cells, named 
parafollicular cells or C cells, are seen.  
The follicular cells are responsible for iodine uptake and L-triiodothyronine 
(T3) and L-thyroxine (T4) synthesis, while C cells are designated for the 
secretion of calcitonin, involved in calcium homeostasis (Figure 1.B). [1, 2] 
 
1.2 PHYSIOLOGY 
The thyroid hormones synthesis is under the control of hypothalamic-
pituitary axis by negative feedback. The hypothalamus secretes the 
thyrotropin-releasing hormone (TRH), which stimulates the release from the 
anterior pituitary gland of thyroid-stimulating hormone (TSH). When the 
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gland receives TSH stimulation, it starts to synthetize hormones, through a 
complex process. First, the iodide (I
-
) is active uptaked in exchange for Na
+
, 
involving ATPase-dependent transport. I
-
 requires to be organify and 
incorporate it into a tyrosine residue within thyroglobulin: this process is 
catalyzed by the heme-containing enzyme thyroid peroxidase (TPO) and 
takes place in the apical membrane of the follicular cell. Once iodinated, 
thyroglobulin is taken up into the colloid where a coupling reaction between 
pairs of iodinated tyrosine molecules occurs. The coupling of two tyrosine 
residues each iodinated at two positions (di-iodotyrosine, DIT) produces T4, 
whilst the combination of DIT with mono-iodotyrosine (MIT) produces T3. 
This coupling is catalyzed by TPO. 
Thyroid hormones are lipid soluble molecules released only after TSH 
stimulation, otherwise they are stores in the colloid. When TSH binds its 
receptor, the G proteins associated with the I loops is activated. There are 
two different G proteins coupled to the TSH receptor, Gs and Gq, and they 
stimulate adenylate cyclase and phospholipase C, respectively. The 
activation of further signal transduction mechanisms stimulate several 
processes involved in thyroid hormone synthesis and release and thyroid 
growth, including iodine uptake, production of hydrogen peroxide and TPO 
and uptake of colloid droplets. 
The thyroid hormones bind to nuclear receptor, with a preferential affinity 
for T3, and they regulate gene expression in target cells. In most tissues 
(excluding brain, spleen and testis) thyroid hormones stimulate the 
metabolic rate by increasing the number and size of mitochondria, 
stimulating the synthesis of enzymes in the respiratory chain and increasing 






Figure 1: A) Anatomy of thyroid gland; B) Histological architecture of a thyroid gland. 
The follicles are the functional unit of the gland. They are a roughly spherical group of cells 
surrounding a central lumen filled with a protein-rich storage material, the colloid. The size 
the follicles varies significantly and they range in size 50-500 μm. T3: L-triiodothyronine; 
T4: L-thyroxine 
 
2 THYROID NEOPLASIA 
Thyroid cancer is the most common malignancy of endocrine system [4]. 
and its incidence rates have rapidly increased over the past years, due to  
earlier detection of small asymptomatic cancers [4, 5] . 
The vast majority (~95-97%) of thyroid neoplasms, both malignant and 
benign, arise from follicular cells (Figure 2). Thyroid cancers are divided 
into well-differentiated thyroid carcinomas (WDTCs) (which include both 
papillary thyroid carcinoma - PTC - and follicular thyroid carcinoma - 
FTC), poorly differentiated thyroid carcinoma (PDTC), and anaplastic 
thyroid carcinoma (ATC). PTC and FTC typically respond to radioactive 
iodine treatment, while PDTC and ATC have a more aggressive behavior 
[6]. A small percentage (~3–5%) of cancers are classified as medullary 
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thyroid carcinomas (MTC) (Figure 2) and arise from parafollicular C cells 
[7]. 
In this thesis, we had focused our attention on follicular cell-derived 
neoplasm. 
2.1 BENIGN AND BORDERLINE NEOPLASM 
Benign or borderline thyroid lesions comprise some neoplasm that do not 
show any invasive or aggressive behavior. 
Follicular adenoma (FA) is a benign neoplasm that arises from follicular 
cell and it is characterized by the presence of glandular structures. FA is 
usually an encapsulated tumor in which the most common architectural 
features are follicular or trabecular. FA could be considered as a precursor 
for some FTC: in fact, they are distinguished histologically only by the 
presence of capsular and/or vascular invasion, and nowadays there is not 
any molecular test to reliably discriminate between FA and FTC [8]. 
Hyperfunctioning thyroid adenoma (HTA), also called toxic adenoma, or 
Plummer adenoma, is a follicular adenoma that is scintigraphically ‘hot’ and 
sometimes associated with overt hyperthyroidism. 
Well-differentiated tumor of uncertain malignant potential (WDT-UMP) is 
a follicular neoplasm with both equivocal nuclear features of PTC and 
capsular/vascular invasion. The vast majority of WDT-UMPs show an 
indolent behavior [9]. 
Noninvasive follicular thyroid neoplasm with papillary-like nuclear features 
(NIFTP) is a non- invasive neoplasm with follicular-growth pattern nuclear 
features of PTC. It was previously known as noninvasive encapsulated 
follicular variant of papillary thyroid carcinoma (EFVPTC) [10]. 
2.2 PAPILLARY THYROID CARCINOMA (PTC) 
PTCs represent 85–90% of thyroid cancers [11, 12] (Figure 2). They 
usually are diagnosed with fine-needle aspiration (FNA) when they presents 
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as painless nodule in neck or cervical node. The invasion of parathyroid 
gland may occur early [13]. 
PTCs show usually a favorable outcome, but 10–15% patients have 
recurrent or persistent disease [10, 12]. In a small percentage (~5%) PTC 
develops distant metastases, especially in lung, bones and central nervous 
system (CNS) [12]. Some different risk factors are known to be involved in 
PTC development such as lymphocytic thyroiditis (e.i. Hashimoto 
thyroiditis) [14], reduced iodine intake, family history and hormonal factor. 
Radiation exposure is an important risk factor with PTC: it has been 
demonstrated an association between its development and radiation 
exposure as a consequence of nuclear fallout after the atomic bombs of 
Hiroshima and Nagasaki, nuclear testing in the Marshall and Nevada, and 
the nuclear accident in Chernobyl or Fukushima [15-18]. 
PTC occurs in about 4.5% of cases as a familial disease, but shows the same 
prognosis as the sporadic one [19]. 
Based on the clinical, pathological, histological and molecular profile, 
according to WHO (World Health Organization) classification PTC could 
be divided in 15 variants, on the basis of size (papillary microcarcinoma), 
growth pattern (follicular, macrofollicular, cribriform-morular, and solid), or 
cellular characteristics (tall cell, hobnail/micropapillary, columnar cell, and 
oncocytic) [10]. Histologically, it is possible to observed psammoma bodies 





Figure 2: Frequency of the main histological types of thyroid cancer. 
 
2.3 FOLLICULAR THYROID CARCINOMA (FTC) 
FTCs are a group of epithelial tumor, showing follicular differentiation but 
no papillary nuclear features. They represent ~5% of all thyroid 
malignancies (Figure 2), and are known to have a common tumorigenic 
pathway with FAs, different from that of PTCs (Figure 3) [20] [21]. 
FTC shows a more aggressive behavior than PTC, and tends to spread to 
distant sites and to metastasize to lymph nodes [22]. Nevertheless, the 
prognosis is similar in age-matched and disease stage-matched patients [23]. 
According to the WHO Classification [10], they could be subdivided in 
three main different types:  




ii) encapsulated angioinvasive follicular carcinoma, that represents 
a type of cancer with limited vascular invasion. It usually shows 
a better prognosis than those with extensive vascular invasion; 
iii) widely invasive follicular carcinoma, which shows an extensive 
invasion of thyroid and extrathyroidal soft tissues.  
 
2.4 ONCOCYTIC (HÜRTHLE CELL) CARCINOMA 
Oncocytic (Hürthle cell) carcinomas represent a rare group (~3–4%) of 
follicular neoplasm [24] (Figure 2), characterized by >75% oncocytic cells 
content. They show a very distinctive granular citoplasmatic eosinophilia, 
due to the aberrant increase in mitochondrial mass [25]. The oncocytic 
tumor is usually encapsulated. If there is not any invasion, they are 
diagnosed as “benign oncocytic adenomas”, with no recurrence after their 
excision. On the contrary, they are considered as “malignant oncocytic 
thyroid carcinomas” (OTCs) when they are invasive and show an aggressive 
behavior, with higher frequency of extrathyroidal extension, local 
recurrence and metastasis to lymph nodes [25].  
Oncocytic thyroid tumors were traditionally considered subtypes of FA or 
FTC, and less frequently of PTC. However, recently, they become a 
separate entity and in WHO classification they are no more considered as a 
subtype of FA or FTC [10]. 
 
2.5 POORLY-DIFFERENTIATED THYROID CARCINOMA (PDTC) 
PDTC is a malignant follicular cell-derived tumor that shows a limited 
differentiation of follicular cell, with a clinical behavior intermediated 
between WDTC and ATC [10, 26, 27]. While some PDTCs arise de novo, 
some of them are due to de-differentiation of FTC or PTC. They represent 
0.5-7% of thyroid malignancies [28, 29] (Figure 2), with no evidence of the 
association between PDTC and radiation exposure [30], while a reduce 
iodine intake may be a risk factor in its development.  
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Clinically, PDTC has a more aggressive behavior than WDTC, with a worse 
prognosis than PTC or FTC. PDTC frequently shows vascular invasion (60-
90% cases) and extension to perithyroidal soft tissue in 60-70% cases; 
distant metastasis are common, especially in lung and bone [27].  
 
2.6 ANAPLASTIC THYROID CARCINOMA (ATC) 
ATCs are aggressive undifferentiated (high grade) carcinoma. Nevertheless 
they represent only the 2 - 5% of all thyroid cancers, ATCs are responsible 
of 40% of deaths from thyroid cancer [10] (Figure 2). ATC often affects old 
patients, with a mean age at diagnosis of ~71 years [31]. 
ATC can develop from more differentiated tumors as a result of 
dedifferentiating steps
 
including the loss of p53 [32], or arises de novo. One 
of the most frequent risk factor is iodine deficiency, and a history of goiter 
was shown to be associated in 80% of patients with ATC [33-35]. 
ATCs often present with local invasion and distant metastases, especially in 
lungs and pleura, brain and bones. A few case have metastases to the skin, 
liver, kidneys, pancreas, heart, and adrenal glands. 
 
3 PRINCIPAL MOLECULAR ALTERATIONS IN 
FOLLICULAR CELL-DERIVED NEOPLASM 
According to an increased knowledge of the genetic pathology of thyroid 
tumors, it is now more clear the association between histological features 
(phenotype) and molecular alterations (genotype) [36]. Moreover, it could 
indicated that different genetic alterations may be associated with specific 





Figure 3: Tumorigenesis in the thyroid gland. [37] 
 
Many different molecular signaling pathways are considered to be involved 
in the development of thyroid cancer, such TSH receptor/cAMP pathway, 
mitogen-activated protein kinase (MAPK) pathway, and PI3K/PTEN/AKT 
pathway. 
 
3.1 TSH RECEPTOR/CAMP PATHWAY  
The thyroid-stimulating hormone receptor (TSHR) is linked to a G protein 
and, as all the other member of the G protein-coupled receptor member, it 
presents the characteristic seven loops transmembrane domain [38]. Cyclic 
adenosine monophosphate (cAMP) plays a crucial role in the TSH-mediated 
cellular response (Figure 4). When TSH binds its receptor, an 
intracytoplasmic conformational change takes place, resulting in the 
dissociation of the Gsα subunit from the G protein complex. Gsα subunit 
10 
 
can interact with two main proteins: adenylate-cyclase and phospholipase C. 
The binding of Gsα to adenylate cyclase produces cAMP, which activates 
cAMP-dependent protein kinase A (PKA) catalyzing the phosphorilation of 
specific serine/threonine residues of selected proteins. The cAMP, through 
the interaction with RAS-associated protein 1 (RAP1), can activates BRAF 
and, consequently, the MAPK pathway. 
Mutations in TSHR or in GNAS (encoding its associated alpha-subunit of the 
stimulatory guanine nucleotide-binding protein - Gsα) genes constitutively 
activate their protein, with stimulation of the cAMP pathway independent 
from the binding of TSH to its receptor. The increased intracellular cAMP 
levels result in the continuous thyroid hormone synthesis and secretion.  
The GNAS gene can be considered as oncogene and it was first described to 
be involved in endocrine neoplasms in 1990 [39]. It is located on the long 
arm of chromosome 20 in humans and encodes multiple gene proteins, 
including Gsα. Most of the molecular alterations occur in the mutational 
hotspot in codons 201 and 227 [39, 40], encoding the GTP-binding domain 
and resulting in a constitutively active GTP-bound protein form [41]. 
TSHR is located in on the long arm of chromosome 14 and encodes for a 
seven-(pass)-transmembrane domain receptors. In 1993, mutations of the 
TSHR gene were first reported [42]: high concentration of genetic 
alterations in the III intracellular loop and VI transmembrane region, both of 
which involved in the interaction with G proteins, were observed [43]. The 
III intracellular loop and VI transmembrane regions This areas correspond 
manly to exon 10 of TSHR gene, that is usually analyzed [41]. Some 
germline mutations in TSHR are involved to non-autoimmune autosomal 
dominant hyperthyroidism [44]. 
TSHR or GNAS activating mutations are often observed in follicular 
adenomas and hyperplastic thyroid nodules, in association with 





Figure 4: Main molecules altered in thyroid neoplasms (in orange) involving G-protein 
linked receptor. 
TSH: thyroid-stimulating hormone; ATP: adenosine-5’-triphosphate; cAMP: cyclic 
adenosine monophosphate; Gα: Gsα subunit of heterotrimeric G proteins; β: β subunit of 
heterotrimeric G proteins; γ: γ subunit of heterotrimeric G proteins; rs: regulatory subunit 
type 1-a of protein kinase A (encoded by PRKAR1A); PKA: protein kinase A; CREB: 
cAMP response element-binding protein (CREB3L2 a CREB3 related protein is rearranged 
with PPARg is a few follicular carcinomas); PIPn: phosphatidylinositol n-phosphate; IP3: 
inositol triphosphate; DAG: diacylglycerol; PKC: protein kinase C. 
 
3.2 MITOGEN-ACTIVATED PROTEIN KINASE PATHWAY 
The mitogen-activated protein kinases (MAPKs) belong to a highly 
conserved family of protein involved in the regulation of many 
physiological processes in mammalian, including cell proliferation and 
differentiation, development, immune function, stress responses and cell 
death (Figure 5).  
When the ligand binds the receptor tyrosine kinase RTK, this event causes 
the dimerization of RTK and the phosphorylation of cytoplasmic domains. 
Cytoplasmatic adaptor proteins binds RTK and in turn attract guanine–
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nucleotide exchange factors (GEFs) to the plasma membrane. GEFs active 
RAS, GTPase protein that becomes transiently active when GEF displaces 
GDP from RAF and allows GTP to bind; RAS then cleaves the bound GTP 
and becomes inactive again. During the time it is active, RAS triggers a 
protein kinase known generally as a mitogen-activated protein kinase kinase 
kinase (MAPKKK). The MAPKKK protein is BRAF, which facilitates 
phosphorylation of the second protein kinase in the cascade, MAPKK 
(MEK) [45]. 
MAPK pathway consists of a core three-component kinase cascade or 
module; MAPKs are activated by the phosphorylation of serine/threonine-
specific residues within signature T–X–Y motif catalyzed by a dual specific 
MAPK kinase (MKK or MEK). Downstream the cascade there are many 
different substrate and effector, such as the p42/p44 MAPKs or extracellular 
signal regulated kinases (ERKs), the Jun N-terminal kinases (JNKs 1–3), 
and the p38 MAPKs (α, β, γ, and δ) [46-48]. 
The constitutive activation of the MAPK pathway is one of the most 
frequent oncogenic events in many human cancers, and in thyroid 
tumorigenesis as well. Pathogenic alterations in MAPK cascade is reported 
in approximately 70% of WDTC, and they can affect tyrosine kinase 
receptor proteins (RET, NTRK1, ALK, MET) or intracellular downstream 
effectors like RAS and BRAF [20, 21, 49]. Rarely different molecular 
mutations in MAPK cascade coexist in the same tumor and this evidence 
suggests that constitutive activation of only one component of the cascade is 
sufficient to promote tumor growth [20, 21, 49]. 
 
3.2.1 Tyrosine Kinase Receptors (RET, NTRK1, NTRK3, ALK) 
Tyrosine kinase receptors are fundamental for signal transduction in many 
pathway, and they are found to have an altered activity in many cancers. In 
thyroid neoplasia, more than 20 tyrosine kinase receptors are reported to be 
involved in tumorigenesis [50]; among these, RET, NTRK1, NTRK3 and 
ALK are the most important.  
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3.2.1.1 RET (rearranged during transfection) 
RET gene is located on the long arm of chromosome 10 (10q11.21) and 
encodes a transmembrane tyrosine-kinase receptor. Three different RET 
isoforms are known, due to an alternative splicing in region 3’ [51]. RET 
receptor consists in a glycosylated extracellular (EC) domain involved in the 
recognition and binding ligands and co-receptors, a single pass 
transmembrane (TM) domain, a juxtamembrane (JM) domain, and two 
intracellular tyrosine kinase domains (TK1 and TK2) required for 
autophosphorylation [52]. A protein complex which includes RET, its 
ligand, and a GFRα co-receptor (Figure 5) is required for the dimerization 
of RET and the activation of downstream signaling, including the RAS-
MAPK kinase and the PI3K/PTEN/AKT pathways [53].  
RET is expressed in many tissue, such as brain, thymus, testis, and cells of 
postulated neural crest origin, including calcitonin-producing thyroid C-
cells, and a variety of neuroendocrine tissues. On the contrary, it is not 
expressed in normal follicular cells [54].  
Some gain of function (GOF) germline RET point mutations are known to 
be responsible of multiple endocrine neoplasia (MEN) type 2 (MEN 2A, 
MEN 2B) and familial medullary thyroid carcinoma (fMTC) [55, 56]. 
Because of GOF mutations frequently occur in the extracellular cysteine-
rich domain or in intracellular tyrosine kinase domain, exons 10, 11, 13, 14, 
15, and 16 are suggested to be screened in patients with suspected fMTC or 
MEN2 [57]. RET mutations are also reported in sporadic MTC in 30-70% of 
cases, in association with aggressive behavior and poor prognosis [57-59]. 
RET is found to be altered in PTC by chromosomal rearrangements that 
create the RET/PTC (because is typically found in papillary thyroid 
carcinoma) oncogenes [60]. RET/PTC rearrangement involves the intron 11 
of RET and it can be a paracentric inversions or an interchromosomal 
translocation. The result of these rearrangements is the fusion of the distal 
part of RET, including the region encoding the tyrosine-kinase domain, with 
heterologous genes that consequently causes an aberrant expression of RET 
in thyroid follicular cells, where it is not normally expressed [60]. More 
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than twenty heterologous genes have been found fused to RET  [18, 61-70], 
usually in thyroid tumors of young patients and children, and in tumors that 
show a classic papillary histology [71]. Rearrangements of RET were 
initially numbered from 1 to 7; the ~90% of all these chromosomal 
alterations that occur in PTC are RET/PTC1 (RET fusion with CCD6; 
coiled-coil domain containing 6 gene) and RET/PTC3 (RET fusion with 
NCOA4, nuclear coactivator 4 gene) [72]. The third most frequent 
rearrangement is RET/PTC2 (RET is fused with PRKAR1A (protein kinase 
cAMP-dependent type I regulatory subunit α. 
After the Chernobyl disaster (1986), a high incidence of RET 
rearrangements were found in PTC, especially in children. That is the main 
evidence of the association of RET/PTC with radiation exposure, both 
therapeutic and environmental [16, 73, 74].  
3.2.1.2 NTRK (neurotrophic receptor tyrosine kinase) 
The NTRK family includes three transmembrane tyrosine kinases receptors, 
NTRK1, NTRK2 and NTRK3 (also known as TRKA, TRKB, TRKC), 
encoded by the NTRK1, NTRK2 and NTRK3 genes, respectively. They are 
mainly expressed in human neuronal tissues and play crucial roles in the 
development and function of the nervous system through activation by 
neurotrophins (NTs)[75]. All NTRK receptors are structured with an 
extracellular domain for ligand binding, a transmembrane region and an 
intracellular domain with a kinase domain. When the ligand binds the 
receptor, it triggers the dimerization of the receptors and phosphorylation of 
specific tyrosine residues in the intracytoplasmic kinase domain. This event 
results into the activation of downstream, including the RAS-MAPK kinase 
and the PI3K/PTEN/AKT pathways (Figure 5) [75].  
NTRK family is known to be involved in cancer development since 1986 
[76], and NTRK1 and NTRK3 play an important role in thyroid 
tumorigenesis. 
The NTRK1, located on the long arm of chromosome 1 (1q23.1), encodes a 
protein which binds the nerve growth factor (NGF) with high affinity. 
Similar to RET receptor, the NTRK1 is not present in normal follicular 
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cells, but it is expressed when the tyrosine kinase domain of NTRK1 is fused 
to the 5’-terminal region of heterologous genes. Consequently, these 
chromosomal rearrangements drive NRTK1 expression in thyroid follicular 
cells. The resulting chimeric products exhibit constitutively active tyrosine 
kinase activity [77-80].  
Seven heterologous genes have been found fused to NTRK1 [63, 68, 81, 
82],but among these the most frequent rearrangements are TPM3/NTRK1 
[83], TPR/NTRK1 [82, 84] and TFG/NTRK1 [85]. NTRK1 rearrangements 
are reported in ~5% of PTCs[77], with a NTRK1 molecular activations 
similar as those described for RET [86].  
 
 
Figure 5: Many of the molecules altered in thyroid cancers (in orange) involving MAPK 
cascade (left and PI3K/PTEN/AKT pathway (right).  
RAS: small GTPase RAS protein; GAP: GTPase activating protein; GEF: guanine 
nucleotide exchange factor; adaptor SH2: adaptor proteins with Src homology regions; B-
RAF: protein kinase BRAF (mitogen-activated protein 3 kinase, MAP3K); MEK: mitogen-
activated protein Erk kinase (mitogen-activated protein 2 kinase, MAP2K); ERK: 
extracellular-signal-regulated kinase (mitogen-activated protein kinase, MAPK); L: ligand; 
GFRa: GDNF-family a coreceptor; PI3K: phosphoinositide 3-kinase; AKT: AKT kinase 





The NTRK3 is located on long arm of the chromosome 15 (15q25.3), and 
encodes NTRK3 which binds the neurotrophin-3 (NT3) growth factor with 
high affinity. Similarly to NTRK1, NTRK3 is not physiologically expressed 
in the thyroid cells, while it is expressed in the CNS.  
The most frequent rearrangement is NTRK3 fusion to the ETS variant gene 
6 (ETV6), resulting in the ETV6/NTRK3 oncogene. ETV6/NTRK3 seems to 
be the most frequent chromosomal rearrangement after RET/PTC in 
radiation-associated thyroid neoplasms, reported in ~15% of radiation-
induced PTCs, typically in cases with follicular architecture (classic PTC 
with a component of follicular growth or follicular variant PTC)[87, 88]. 
ETV6/NTRK3 rearrangement has been reported in approximately 2% of 
PTCs not associated with radiation. ETV6/NTRK3 was observed in many 
different neoplasia, as congenital fibrosarcoma, congenital mesoblastic 
nephroma, and secretory carcinomas of the breast and salivary gland; 
however, in PTC it shows the fusion points of the chimeric products 
(usually ETV6 exon 4-NTRK3 exon 14) different from those observed in 
most extrathyroid neoplasms (ETV6 exon 5-NTRK3 exon 13) [87] . 
Two other NTRK3 rearrangement were also reported: RBPMS/NTRK3 [63] 
and SQSTM1/NTRK3 [18]. 
NTRK-rearrangement is a typical alteration found in PTCs from young 
patients and children, with lymph node metastases and aggressive behavior, 
similarly to RET-rearranged cancers [78, 79]. 
 
3.2.1.3 ALK (anaplastic lymphoma kinase) 
ALK is located in the short arm of chromosome 2 (2p23) and encodes a 
transmembrane tyrosine kinase receptor. Through the binding with its 
lingands pleiotrophin (PTN) and midkine (MK), both growth factor, ALK 
plays an active role in the development of the central and peripheral nervous 
systems [89]. The first evidence of ALK as an oncogene was in 1994, when 
it was found to be fused to NPM1 in an anaplastic large-cell non-Hodgkin's 
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lymphomas (ALCL) [90]. Since then, different tumors harboring ALK 
alterations (including rearrangement, mutation, and amplification) were 
identified, such as non-small cell lung carcinoma (NSCLC), mesenchymal 
neoplasms, and neuroblastoma [91]. When it is altered, ALK is aberrantly 
activated and promotes cell proliferation and survival through MAP kinase 
and PI3K/PTEN/AKT pathways (Figure 5) [92, 93]. 
ALK rearrangements seem to be in association with radiation exposure and 
aggressive clinical-pathological features. ALK is fused to EML4 in ~13% of 
PTC with solid/trabecular architecture, high radiation dose, and younger age 
[94]. ALK/STRN was described in 9% percent of PDTC and in 4% of ATC 
[95, 96]. A small percentage of PTCs (~1%) harbors STRN/ALK, and these 
tumors show a predominance of follicular growth pattern [95]. With a lower 
frequency, other 5 ALK rearrangement were describe in high grade thyroid 
cancers [64, 68, 97, 98]. 
ALK rearrangements could be a predictive marker because patients with 
ALK-rearranged cancers may respond to target therapies with ALK 
inhibitors (e.g. crizotinib) [95]. 
 
3.2.2 BRAF 
The RAF family includes three different isoforms of serine-threonine 
kinase: ARAF, BRAF, and CRAF (also called RAF-1) [99]; they are all 
intracellular effectors of the MAPK signal transduction pathway (Figure 5). 
Structurally, the RAF proteins present three conserved regions (CR): CR1 
and CR2 at the N-terminus and CR3 at the C-terminus [100, 101]. The 
RAS-binding domain (RBD) is in CR1, while CR2 is a serine/threonine rich 
domain, containg a site, when phosphorylated, that can bind to 14-3-3, a 
regulatory protein. CR3 contains the kinase domain responsible for RAF 
activation and MEK1/2 phosphorylation. In CR3 domain there is the 
important aspartate-phenylalanine-glycine (DFG) motif, which plays a 
fundamental role for the regulation of the ATP-binding pocket [100]. 
Activating mutations, such as BRAF p.V600E, can destabilize and disrupt 
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the inactive conformation of the DFG motif, resulting in a constitutively 
activated protein state [102]. 
The BRAF gene (v-raf murine sarcoma viral oncogene homolog B) is 
located on the long arm of chromosome 7 (7q34) and encodes a full-length 
protein of 766 amino acids (94 kDa) [99, 103, 104]. Since the discovered of 
activating alterations, BRAF was found to be mutated in  malignant 
melanoma (27%-70%), thyroid cancers (40-45%), colorectal cancer (5%-
22%), serous ovarian cancer (~30%) and in other human cancers with a 
lower frequency (1%-3%) [105-108]. Activating point mutations of BRAF 
occur in the kinase domain encoded by exons 11 and 15. Differently from 
other cancers, no mutations in exon 11 were found in thyroid neoplasia 
[105-107, 109]. Mutated BRAF proteins have been divided into three 
groups, according to the activation of downstream molecules, such as MEK: 
i) high activity (i.e. p.V600E and p.K601E); ii) intermediate activity; iii) 
impaired activity [102]. Unlike the BRAF p.V600E substitution, the 
mechanism of activation of downstream protein in MAPK pathway through 
wich “uncommon” BRAF mutants act is not fully understood. 
Among the alterations observed in BRAF, ~95% consists in a point mutation 
in exon 15, that involves nucleotide 1799 (thymine to adenine transversion, 
c.1799T>A), resulting in a valine to glutamate substitution at residue 600 
(p.V600E) [20, 110, 111]. BRAF p.V600E mimics the phosphorylation of 
the activation segment, that results in a constitutive activation of BRAF. 
BRAF p.V600E is typically found in PTC with a tall cell architecture (80%) 
or with a classical histology (60%), while it is rarely observed in the 
follicular variant of PTC (10%) [20, 110, 112, 113], in which point mutation 
other than BRAF p.V600E (e.g. p.K601E) are found [114, 115]. Therefore, 
the presence of these mutations can be used as a diagnostic marker for PTC. 
BRAF p.V600E has also been described in PDTC and ATC (24%), 
especially in those derived from BRAF p.V600E positive tumors [116]. 
Several studies have shown a correlation between this alteration and a worst 
outcome for BRAF p.V600E -positive patients, and it was demonstrated to 
be a poor prognostic factor independent from other clinic-pathological 
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features [117-119]. Whereas, other studies have not confirmed the role of 
BRAF p.V600E as a tumor aggressiveness-related factor [120-122]. For 
these reasons, the prognostic role of BRAF p.V600E is still controversial. 
BRAF p.V600E is also considered a predictive marker: tumor harboring this 
alteration respond to kinase inhibitor (dabrafenib and vemurafenib) [123]. 
Other non- BRAF p.V600E mutations are reported in 1-2% of PTC; they 
include other point mutations, small ins/del and chromosomal 
rearrangements [124]. Among point mutations, BRAF p.K601E is related to 
neoplasm with a follicular architecture: it was detected in FA and in 7-10% 
of the follicular variant of PTC [49, 125]. Twenty-one different BRAF 
rearrangements have been reported in relation with PTC or high grade 
thyroid cancers [63, 68, 126-129]. 
 
3.2.3 RAS 
The H-RAS, N-RAS and K-RAS oncogenes belong RAS superfamily, 
composed by more than 150 21-kDa G proteins that play a crucial role in 
MAPK and PI3K/PTEN/AKT pathways (Figure 5), contributing to the 
control of proliferation, differentiation, and survival of eukaryotic cells 
[130]. As a G-protein, RAS proteins cycle between active GTP-biding form 
and inactive GDP-biding states, with a highly conserved mechanism. The 
conversion from the inactive form to the active one is under the stimulation 
of GEFs, while the conversion to the inactive form is cotrolled by GAPs. 
Besides cancers, alteration in RAS signaling are known to be involved in the 
development of many pathologies, such as non-obese diabetes and diabetic 
retinopathy, hyperinsulinemia [131-133], glomerulonephritis [134]. 
Activating RAS point mutations are concentrated in two hotspot of the 
primary nucleotide sequence of all RAS family members. They can affect 
the GTP-binding domain (exon 2, codons p.G12 or p.G13) or the GTPase 
domain (exon 3, codon p.Q61) which “lock” the protein in the active GTP-
bound form and constitutively activate the protein [135, 136]. Constitutive 
activation of KRAS, NRAS, and HRAS is one of the most common events in 
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human tumorigenesis. About 30% of all human neoplasia is found to harbor 
mutation in any of the canonical RAS genes, predominantly K-RAS (25-
30%), while N-RAS and H-RAS occur with lower  frequency (8% and 3%, 
respectively) [137]. In thyroid tumor, mutation in RAS oncogenes are 
described in those whose arised from the follicular epithelium, 
predominantly with a follicular growth pattern. It has been reported in 5-
10% of hyperplastic thyroid nodules [138] and in 20-50% of follicular 
carcinoma, follicular adenoma, and the follicular variant of papillary 
carcinoma [20]; while they are uncommon in conventional papillary 
carcinomas. The high frequency in both PDTC and ATC could indicate their 
involvement in progression and their association with carcinomas with 
aggressive clinic BRAF p.V600E -pathologic features and poor prognosis 
[139-141]. 
Oncogenic RAS activation also occurs in medullary carcinoma, and it seems 
to be mutual exclusive with that of RET [142-144]. The more frequently 
mutations are in H-RAS and K-RAS genes, while N-RAS mutations are quite 
uncommon [136, 142-144]. 
 
3.3 PI3K/PTEN/AKT PATHWAY 
The PI3K/AKT/PTEN pathway has an important role in regulating 
metabolism, cell growth, and cell survival as well as carcinogenesis, tumor 
growth and angiogenesis [145]. When the ligand bind its TRK, the receptor 
starts the dimerization, and subsequently increases PI3K activity in 
producing both phosphatidylinositol-3,4-diphosphate (PIP2) and 
phosphatidylinositol-3,4,5-triphosphate (PIP3). These events active PDK1 
and AKT which is involved in the regulation of multiple cellular functions 
(metabolism, protein synthesis, cell cycle progression, anti-apoptosis, tumor 
growth, and angiogenesis) through different downstream targets (Figure 5). 
The PI3K family comprehend signal transducer enzymes responsible of 
PIP2 and PIP3 production and AKT activation. They are divided into three 
classes (class I, class II, and class III); the production of PIP3 is a unique 
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activity of class I, which consists in proteins activated by RTKs (class IA) 
or G-protein-coupled receptors (class IB) [146]. PI3K presents a catalytic 
subunit (p110), wich generates PIP3, and a regulatory subunit (p85), 
involved in receptor binding and activation / localization of the enzyme. In 
class IA three genes, PIK3CA, PIK3CB and PIK3CD, are involved in 
encoding p110 isoforms: p110α, p110β and p110δ, respectively. Subunit 
p110α and p110β are known to be ubiquitously expressed, while p110δ is 
expressed only in immune system [147-149].  
AKT (protein kinase B [PKB]) is a family of serine/threonine-specific 
protein kinases which is the major downstream target of PI3K. In human, 
AKT presents three isoforms, AKT1, AKT2, and AKT3 [150]; all of them 
are expressed in the normal thyroid, but AKT1 and AKT2 are the most 
abundant [151, 152]. Once PIP3 binds and activates phosphoinositide-
dependent kinase 1 (PDK1), PDK1 phosphorylates AKT in the kinase 
domain, represented by the residue Thr308 in AKT1. AKT1 is fully 
activated by the additional phosphorylation Ser473, involving PDK2 [153]. 
The active form of AKT phosphorylates several downstream targets such as 
mTOR complex [154], playing an important role in regulation of various 
cellular functions, including proliferation, survival, and metabolism.  
PTEN (phosphatase and tensin homolog deleted on chromosome 10) is a 
dual function protein: it acts as phosphatase on protein and lipid, and 
negatively regulates the activity of PI3K/AKT signaling through the 
dephosphorylation of phosphoinositide substrates and the convertion of 
PIP3 to PIP2 [155]. For this reason PTEN (localized in 10q23.31) is a tumor 
suppressor, which it is often inactivated through different mechanisms.  
Deregulation of PI3K/PTEN/AKT pathway is known to be associated with 
tumor progression in thyroid cancer: this is a common alteration found in 
high grade cancers, with an aggressive behavoiur (PDTC and ATC). 
Activating somatic point mutations of PI3K are described in PIK3CA 
(mapped in 3q26.3), clustered in exon 9 (encoding for the helical domain) 
and in exon 20 (encoding for the for kinase domain). PIK3CA copy number 
gains are also known, but their tumorigenic role is less defined. Point 
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mutations have been reported in 0-10% of FTC and in 0-25% of PDTC and 
ATC, while copy number gains were identified in approximately 25% of 
FTC and in 40% of ATC, but their tumorigenic role is less defined [156-
159]. 
Alteration in AKT signaling are caused both by dysregulation of PI3K 
function, as well as PTEN  Loss of Function (LOF) alteration [157]. 
Moreover, mutations in AKT1 are known to constitutively activate AKT 
signaling 15%of high-grade, aggressive, radioactive iodine-refractory forms 
of thyroid cancer [160]. 
PTEN mutations have been reported in sporadic thyroid tumors in 0-10% of 
FTC and in 5-20% PDTC and ATC. However, loss of heterozygosis or 
epigenetic mechanisms (such as PTEN promoter methylation) are a more 
common in cancer, causing the decreased of PTEN mRNA and protein 
levels [157, 161-164]. Germline PTEN LOF mutations are responsible for 
Cowden syndrome, an autosomal dominant condition characterized by 
multiple benign tumors and hamartomatous proliferations at various sites 
[165]. 
 
3.4 PPARγ  REARRANGEMENT 
PPARγ (peroxisome proliferator-activated receptor γ) belongs to the 
nuclear receptor family of transcription factors, involved in regulation of 
lipid metabolism (adipogenesis) and insulin sensitivity [166, 167]. PPARG 
maps in the short arm of chromosome 3 (3p25.2) and encodes for protein 
with a classical nuclear hormone receptor structure: a N-terminal regulatory 
“AB” domain; centrally it shows a zinc finger DNA binding domain, and a 
ligand binding/transcriptional regulatory domain at the C-terminal (Figure 
6.A). Two isorforms, PPARγ1 and PPARγ2, are known, and they seem to 
have a similar function, but they differ for 30 amino acid (PPARγ2 is longer 
than PPARγ1) and they have a different expression pattern (PPARγ2 is 
expressed specifically in adipocytes). In thyroid, PPARγ expression level 
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tends to be very low, but it becomes higher when PAX8/PPARγ 
rearrangement is detected [168, 169].  
PAX8 (paired box gene 8) belongs to a transcription factor family, involved 
in the genesis and differentiation of thyroid follicular cell, driving the 
expression of many thyroid-specific genes such as those encoding 
thyroglobulin, thyroid peroxidase and the sodium iodide symporter [170]. 
PAX8 gene consists in 12 exons, with the DNA binding domain (DBD) 
encoded by exons 3, 4 and the beginning of exon 5, while the transcriptional 
activation domain is encoded by exons 10 and 11 (Figure 6.B). Alternative 
splicing of exons 8-10 results in 5 protein isoforms, PAX8A, B, C, D and E, 
among which PAX8A is the longest isoform and includes all codons from 
exons 2-12. PAX8B is shorter than PAX8A because of the deletion of exon 
9, without the alteration of the reading frame of downstream exons. PAX8C 
presents a smaller exon 9, derived from an alternative splicing; the result of 
this event is a altered reading frame shift, with the stop codon in exon 11. 
Both PAX8D and PAX8E are shorter than PAX8C (PAX8D harbors the 
deletion of exons 8 and 9, while PAX8E is deleted in exons 8, 9 and 10), but 




Figure 6: Schematic representation of the PPARG gene (A) and PAX8 gene (B). The 
exons are not drawn to scale. A) Coding exons are shown in blue, noncoding in white, 
while the protein is in green. Only the PPARG exons that contribute to the PPARγ1 protein 
are shown, and for convenience they are numbered starting at 1 (the gene has several 
additional upstream exons). B) Coding exons are shown in violet, noncoding in white, 
while the protein is in orange. The reading frame shift is shown by a darker shade of orange 
within the exons. 













The PAX8/PPARG rearrangement is a translocation involving the long arm 
of chromosome 2 and the short arm of the chromosome 3 [t(2;3)(q13;p25)] 
(Figure 7) [172]. This alteration results in a fusion transcript wherein most 
of the coding sequence of PAX8 (including its promoter region) is fused in 
frame with the entire coding exons of PPARγ1. Because of the high activity 
of PAX8 promoter, PAX8/PPARγ Fusion Protein (PPFP) is highly 
expressed in follicular thyroid cells harboring this translocation [173]. 
. 
 
Figure 7: Schematic representation of PAX8/PPARγ Fusion Protein (PPFP). Typically, 
the fusion involve PAX8 exons 1-10 with the entire sequenzìce of PPARγ1. The resulting 
PPFP consists of an N-terminal PAX8 fragment encoded by exons 2-10 fused in frame to 
full length PPARγ1. The PAX8 portion is essentially a truncated version of PAX8A, 
missing much of the C-terminal activation domain. 
Not shown, PAX8 variants result in alternative isoforms of PPFP that only include PAX8 
exons 1-8, or 1-9, or 1-10 without exon 9. 




A second rearrangement of the PPARG involves the gene CREB3L2 
(mapped at 7q34) [t(3;7)(p25;q34)]: the fusion results in PPARG fused in 
frame with CREB3L2 exons 1 and 2 [174]. CREB3L2/PPARG is much less 
common than PAX8/PPARG, with an estimated prevalence lower than 3 
percent among follicular carcinomas. It has been reported in one radiation-
associated follicular variant papillary carcinoma that developed in a child 
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exposed to the Chernobyl radioactive fallout [88]. CREB3L2/PPARg has not 
been identified in benign or non-malignant thyroid tissue [88]. 
PAX8/PPARG typically occurs in follicular-patterned neoplasias: it is 
reported in 20-50% of FTC, in FTA and in PTC-EFV, but with a lower and 
variable frequency [175-178]. PAX8/PPARG is very rare in PDTC and ATC 
[97, 160]. 
CREB3L2/ PPARG has been reported with a lower frequency (~3%) in FTC 
and in ~1.5% of PTC-EFV [179]. 
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Aim of the study 
This study has two Aims. 
Aim1. The molecular profile of Papillary Thyroid Carcinomas has been 
deeply investigated. However, to date, there are no informations regarding 
the molecular profile of the non-malignant tissue surrounding the PTC. 
Exploring the molecular signature, and in particular the BRAF status, of the 
non- neoplastic tissue surrounding the tumor may help to better understand 
thyroid tumorigenesis and the events that lead potential  precursor lesions to 
evolve to papillary carcinoma. 
The first aim of this project is to establish whether BRAF mutations are 
present in non-malignant tissue surrounding PTC, and in case they are found 
to characterize their activity in vitro. 
Aim 2. The combination of cytologic analysis and molecular testing is 
improving the pre-operative evaluation of thyroid nodules. The definition of 
molecular panels can be very useful to inform treatment, to establish the 
best surgical approach, and to stratify patient risk. 
The second aim of this project is to set up a RNA based expression panel 
that may provide diagnostic, predictive and prognostic information on 
thyroid nodules/neoplasms. 
Next Generation Sequencing techniques, mutagenesis, cell transfection, and 
protein functional assays were used to achieve these aims. 
28 
 
Materials and Methods 
Aim 1: Detection of BRAF mutations in neoplastic and 
non-malignant tissue and analysis of BRAF-mutant 
activity 
1 NEXT GENERATION SEQUENCING 
1.1 CASES SELECTION 
In the present study, we analyzed the BRAF molecular status of 30 PTCs 
including 100 areas from tissues surrounding the tumor. The age of the 
patients ranged from 29 to 79 years (mean 48.3 years; median 49.0 years). 
Ten patients were male (33.3%) and 20 were female (66.7%) (Table 1). 
Non-malignant tissues were classified as following (Table 1): i) 
characterized by the presence of hyperplasia (“HYP”- n=16); ii) 
characterized by the presence of “atypia” (“ATY” - n=38). Atypical thyroid 
tissue was defined by the presence of unusual features, including follicular 
cells showing some crowding and minor alterations of the nuclear 
morphology, such as mild nuclear clearing, mild enlargement and contour 
irregularities, similar to what described in multifocal fibrosing (sclerosing) 
thyroiditis [180]; iii) areas containing psammoma body (“PsB” - n=6); iv) 
tissue with typical thyroidal architecture (“NORM” - n=34);  
Malignant neoplasia analyzed in this study were: i) 15 PTC-CL (50.0%); ii) 
9 PTC-FV (30.0%); iii) 5 PTC-TC (16.7%); iv) one sclerosing PTC (3.3%) 
(Table 1). Moreover, the following areas with non-malignant neoplasia 
were analyzed: i) follicular adenoma (“FA” - n=4):; ii) follicular adenoma 






Features n % (n=30) 
Sex 
  
Male 10 33.3 
Female 20 66.7 
Malignant histotype  
 
% (n=30) 
PTC-CL 15 50.0 
PTC-FV 9 30.0 
PTC-TC 5 16.7 
Sclerosing PTC 1 3.3 
Non-malignant tissue  
 
% (n=100) 
ATY 38 38,0 
HYP 16 16,0 
NORM 34 34,0 
FA 4 4,0 
PsB 6 6,0 
FA-OC 2 2,0 
Table 1: Features of cases.  
 
1.2 DETECTION OF BRAF MUTATIONS 
1.2.1 DNA extraction and quantification 
All samples were formalin-fixed and paraffin-embedded (FFPE) and were 
retrieved from the archives of Anatomic Pathology Unit of Bellaria and 
Maggiore Hospital (Bologna, Italy) from 2009 to 2011. 
DNA was extracted from two to four 10-µm-thick sections using the 
HighPure PCR Template Preparation Kit (Roche-Diagnostic, Manheim, 
Germany), scraping the area of interest with a sterile blade, according to the 
selection performed by the anatomic pathologist on the haematoxylin and 
eosin (H&E) stained slide. 
The concentration of the extracted DNA was assessed using the Quant-iT™ 
dsDNA BR Assay Kit using a Qubit™ Quantitation Platform 
(ThermoFisher Scientific, Waltham, MA, USA). 
1.2.2 Amplicon library preparation 
Next Generation Sequencing (NGS) was performed using the 454 GS-




Briefly, at least 10 ng of DNA was amplified targeting BRAF exon 15, 
using the following primers: Sense 5′-
TGCTTGCTCTGATAGGAAAATGA-3′ and Antisense 5′- 
TGGATCCAGACAACTGTTCAAA -3′ (Table 5).  
 
 
Figure 8: 454 Next-Generation Sequencing primers. 
 
Primers were modified and they were made up to 3 parts (Figure 8):  
- a universal sequencing tail (A and B) is composed of an adaptor and 
a “key”. The adaptor sequences (A and B) are involved the EmPCR. 
The “key” is composed of a four nucleotide sequence (TCAG) that 
allows the instrument to recognize where the amplicon sequence 
starts; 
- multiple identifiers nucleotide sequences (MIDs) are a unique DNA 
barcode that allows the instrument to identified each sample;  
- template specific sequence. 
 







Reaction mix (final volume 25µl) 
Reagent Concentration 
dNTP (Roche) 0.2 mM 
FastStart High Fidelity Reaction 
Buffer 
1X 
MgCl2 Solution 1mM 
FastStart High Fidelity Enzyme 
Blend 
1.25 U 
Primers (both FW and REV) 6.25pmol 
Molecular biology grade water - 
PCR steps 
Temperature (°C) Time No. of cycles 
95 2' 1 
95 30'' 37 
60 30''  37 
72 1'  37 
72 7' 1 
Table 2. Reaction mix and PCR steps used for amplicon library preparation. 
 
1.2.3 Library purification and quantification 
For the amplicon library purification magnetic beads were used (Agencourt 
AMPure XP PCR Purification, Beckman Coulter). Briefly, PCR products 
were mixed and incubated at room temperature with magnetic beads. Then, 
in order to separate amplicons bound to magnetic beads from contaminants, 
a magnet was used (Agencourt SPRIPlate 96 Super Magnet Plate).  
After two washes with ethanol 70%, amplicons were eluted in 20 μl of 1x 
TE Buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA, Sigma-Aldrich). 
Purified amplicons were then quantified using the Quant-iT PicoGreen® 
dsDNA quantitation Assay Kit (ThermoFisher Scientific, Waltham, MA, 





1.2.4 Amplicons dilution, pooling and EmulsionPCR 
Based on the concentration, amplicons were diluted with 1x TE Buffer in 
order to obtain 1x10
9
 molecules/µl per each well. The amplicon were pooled 
and further diluted in molecular biology grade water to reach the desired 
concentration. 
An EmulsionPCR (EmPRC) were carried out. Biefly, two identical reaction 
mix (Table 3), except for sequencing primers, were prepared. After 2 
washes, amplicons dilution (12 µl) and both mix A and B (600 µl) were 
added to Capture Beads A and Capture Beads B, respectively. 
 
Reaction mix (final volume 600 µl) 
Reagent Volume (µl) 
Additive 260 
Molecular biology grade water 205 
Enzyme Mix, 35 
Amp Mix 135 
PPiase 1 
Primers (A and B) 40 
PCR steps 




94 30'' 50 
56 4’30''  50 
68 30’’  50 
10 Up to 16h 1 
Table 3: Reaction mix and steps used for EmPCR. 
 
1.2.5 Recovery and enrichment  
The emulsion was broken and beads recovered. In order to separate DNA-
carried  beads from mixed or empty one, an enrichment process was 
performed. Briefly, after an incubation with a Melt Solution (containing 
NaOH), “Capture Beads” were then incubated with biotinylated Enrich 
Primer A and Enrich Primer B. Using streptavidin-coated magnetic beads 
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(Enrichment Beads) and a Magnetic Particle Concentrator (MPC), “empty” 
(i.e. without amplicons) beads were separated and discard.  
Sequencing Primers were added to the beads, and aliquoted to a 
PicoTiterPlate (PTP) with Packing Beads, Enzyme Beads and PPiase 
beads. The sequencing was then carried out. 
Results were analyzed using Amplicon Variant Analyzer (AVA) software 
(Roche Diagnostic, Mannheim, Germany). Only nucleotide variations 
observed in both strands, with at least 1% of allele-read were considered 
for the mutational calling  
 
2 SITE-DIRECT MUTAGENESIS AND CELL 
TRASFECTION 
2.1 MUTANT BRAF PLASMIDS GENERATION VIA SITE-
DIRECTED MUTAGENESIS 
The construct pCMV6 encoding wild-type BRAF (#40775) was purchased 
from Addgene (Cambridge, MA USA) in frame with the tag FLAG. 
Mutations p.G593D, p.A598T, p.V600E, p.K601E, p.S607F and p.S607P 
were inserted using the Q5 Site-direct Mutagenesis kit, according to the 
manufacturer’s instruction (New England Biolabs, Ipswich, MA, USA). The 
oligonucleotides used for the mutagenesis are reported in Table 5. Briefly, 














Reaction mix (final volume 25 µl) 
Reagent Concentration 
Q5 Hot Start High-Fidelity 2X 
Master Mix 
1X 
Primer FW (10 µM) 0.5 µM 
Primer RV (10 µM) 0.5 µM 
Template DNA  1–25 ng/µl  
Molecular biology grade water - 
PCR steps 
Temperature (°C) Time No. of cycles 
98 30’’ 1 
98 10’’ 25 
60 30’’ 25 
72 30’’  25 
72 2’ 1 
10 - 1 
Table 4: Reaction mix and steps used for mutagenesis. 
 
Amplified plasmidic DNA were incubate with Kinase-Ligase-DpnI (KLD) 
enzymes and competent cell (NEB 5-alpha Competent E. coli) were 
transformed.  
Plasmid DNA extraction were performed using Plasmid Plus Midi Kit 
(QIAGEN, Germantown, MD, USA) following manufacturer’s instructions. 
The site-directed mutagenesis was verified by plasmid direct sequencing 
(PE Applied Biosystems) using BRAF exon 15-targeting primers (all 








































Table 5:Primer used for NGS 454-gs Junio, mutagenesis, Sanger sequencing and vector 
sequencing. In bold the nucleotide involved in the mutation 
 
2.2 CELL TRANSFECTION 
For transient transfection, 4x10
5
 cells HEK293 were seeded in complete 
medium and incubated at 37 °C in a humidified atmosphere with 5% CO2. 
After 24 hours, 4 μg of BRAF mutant plasmids were transfected using 
liposomes according to the manufacturer’s instructions (Lipofectamine 
3000, ThermoFisher Scientific). 48 hours after transfection, cells lysates 
were produced using RIPA buffer. 
 
3 WESTERN BLOT 
Cells were lysed in ice-cold RIPA buffer: 50 mM HEPES (EuroClone, 
Milan, Italy), 1 mM EDTA (Sigma-Aldrich), 10% glycerol (ThermoFisher 
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Scientific), 1% Triton X-100 (Sigma-Aldrich), 150 mM NaCl in the 
presence of proteases and phosphatases inhibitors (Sigma-Aldrich).  
Total protein was measured using the Lowry protein assay kit (Biorad DC 
Protein Assay; Biorad, Hercules, CA USA) according to the manufacturer’s 
instruction. Protein samples (15 μg) were subsequently separated 4-20% 
pre-cast gels (ThermoFisher Scientific). Gels were then electro-transferred 
onto nitrocellulose membranes (Trans-Blot Turbo Transfer System, Biorad). 
Membranes were blocked in Tris Buffered Saline (TBS) with 1% Casein 
(Biorad) for 1 hour at room temperature and incubated with primary 
antibodies at 4°C overnight. Membranes were washed three times in Tris-
buffered saline containing 0.1% Tween and incubated with peroxidase-
conjugated secondary antibodies for 45 minutes at room temperature. 
 Bands were visualized using WESTAR Supernova (Cyanagen, Bologna, 
Italy) and detected with the ChemiDoc™ XRS+ (Biorad). Densitometric 
analysis have been performed with ImageLab software (Biorad). 
Primary antibodies were used against: phospho-ERK (Thr202/Tyr204) 
(rabbit, 1:1000), total ERK (mouse, 1:1000), phospho-MEK (Ser217/221) 
(rabbit, 1:250), total MEK (mouse, 1:250), phospho-BRAF (Ser445) (rabbit, 
1:250), total BRAF (rabbit, 1:250), vinculin (mouse, 1:10,000), γ-tubulin 
(mouse, 1:10,000) (all purchased by Cell Signalling, Leiden, Netherlands) 
and FLAG tag (mouse, 1:10,000, Sigma-Aldrich). Peroxidase-conjugated 
secondary antibodies used were: anti-mouse IgG (1:10,000; Sigma-Aldrich) 















Antibody Weight (KDa) Dilution Animal origin Source 
anti-phospho-ERK 
(Thr202/Tyr204) 
42-44 1:1000 Rabbit 
Cell Signaling 
Technology 





45 1:250 Rabbit 
Cell Signaling 
Technology 





94 1:250 Rabbit 
Cell Signaling 
Technology 
anti-BRAF 94 1:250 Rabbit 
Cell Signaling 
Technology 
anti-FLAG 94 1:1000 Mouse Sigma-Aldrich 
anti-γ-Tubulina 46 1:10000 Mouse 
Cell Signaling 
Technology 




anti-mouse IgG - 1:10000 - Sigma-Aldrich 
anti-rabbit IgG - 1:10000 - Sigma-Aldrich 




Aim 2: Design and set up of a gene expression panel. 
4 GENE PANEL DESIGN  
The RNA-based expression panel was designed to detect fusion and to 
identify dysregulated expression of genes known to be altered in thyroid 
cancer, and with the potential for diagnostic and clinical relevance. 
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For this RNA-based panel, primers were designed to detect 30 gene fusions, 
9 expressed fusion genes, 16 genes involved in biomarker and thyroid 
lineage and differentiation, 18 genes involved in immune-oncology, 42 
genes differently expressed in BRAF-like or RAS-like cancers, 5 genes 
up/down regulated in cancers, 38 proliferation genes. Moreover, 27 
housekeeping genes were included (Table 7 and Supplementary Table 1). 
 
Main pathways related to genes 
investigated  
No. Breakpoints 
Gene Fusion 30 93 
Expressed fusion 9 - 
BRAF-like signature 22 - 
RAS-like signature 16 - 
RET signature 4 - 
 Down/Up regulated in carcinoma 5 - 
Immumo-oncology 18 - 
Lineage 6 - 
Biomarker 2 - 
Thyroid differentiation score  8 - 
Proliferation 38 - 
Housekeeping 27 - 
Table 7. Genes included in the panel. 
 
 
5 SELECTION OF CASES 
We analyzed 44 fresh-frozen (FF) samples to test our expression panel. 
Fourty-one FF specimens were from thyroid gland. The age of the patients 
ranged from 15 to 82 years (mean 43.5 years; median 43.0 years). Ten of 
41 patients were male (24.4%) and 31 were female (75.6%). 
FF specimens included (Table 8): i) normal thyroid tissue (n=3); ii) 
hyperplastic thyroid tissue (n=4); iii) follicular adenoma (n=3); iv) Hürthle 
cell carcinoma (n=3); v) PTC-CL (n=9); vi) PTC-TC (n=5); vii) PTC-FV 
(n=5); viii) FTC (n=4); ix) ATC (n=3); x) MTC (n=1). 














Normal tissue (n=3) - - - 3 
Hyperplastic tissue (n=4) - - - 4 
Follicular adenoma (n=3) - 2 - 1 
Hürthle cell carcinoma 
(n=3) 
- - - 3 
PTC-CL (n=9) 9 - - - 
PTC-TC (n=5) 5 - - - 
PTC-FV (n=5) 1 4 - - 
FTC (n=4) - - 3 1 
ATC (n=3) 2 - - 1 
MTC (n=1) - - - 1 
Table 8. Fresh Frozen specimens tested for the custom RNA-based panel. 
 
6 NEXT GENERATION SEQUENCING 
6.1 DNA AND RNA EXTRACTION 
Fourty-four FF samples were analyzed. They were all retrieved from the 
archives of Pathology Unit of the University of Michigan (Ann Arbor, 
Michigan, USA) from 1995 to 2003. All samples were previously 
characterized using Affymetrix microarray analysis (ThermoFisher). 
DNA and RNA were extracted using AllPrep DNA/RNA Kit (Qiagen) 
following manufacturer’s instruction.  
The concentration of the RNA extracted was assessed using the Quant-iT™ 
RNA BR Assay Kit on a Qubit™ Quantitation Platform (ThermoFisher 
Scientific, Waltham, Massachusetts, USA). 
 
6.2 RETROTRANSCIPTION AND NEXT GENERATION 
SEQUENCING PROTOCOL 
RNA retrotranscription and NGS were carried out using Ion S5 XL platform 
(LifeTechnologies), following manifacturer’s instruction. 
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Briefly, 10ng of RNA were reverse transcribed as reported in Table 9. 
Target genes were then amplified using RNA custom panel, following 
condizione reported in Table 10. 
 
Reaction Mix 
Component Volume (μl) 
5X VILO RT Reaction Mix 2 
10X Superscript III Enzyme 
Mix 
1 
Total RNA (10ng) ≤ 6 
Nuclease-free Water to 10 
Protocol 




Table 9. Reaction mix and steps used for RNA retrotranscription. 
Reaction Mix 
Component Volume (μl) 
5X Ion AmpliSeq HiFi Mix 4 
5X Ion RNA panel  1 
Nuclease-free Water 2 
  
RT product 10 
Protocol 





Table 10. Amplification condition of RT product. 
 
After a partial digestion of primer sequences with FuPa Reagent, each 
sample was “barcoded” using Ion P Adapter and Ion Ampliseq Barcode. 
Barcoded amplicons were purified using a two-round purification, based on 
the use of magnetic beads.  
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The library was amplified using reagent and prorocol reported in Table 11. 
 
Reaction Mix 
Component Volume (μl) 




primer mix   
2 
Purified library 10 
Protocol 




10 ≤ 24 hours 
Table 11. Condition used for library amplification. 
 
Amplified amplicons were then purified and quantified using Quant-iT™ 
dsDNA HR Assay Kit on a Qubit™ Quantitation Platform (ThermoFisher 
Scientific). The amplicon library was then diluted to a concentration of 
approximately 15ng/ml.  
The sequencing was then carried out on Ion S5 XL platform. 
 
7 STATISTICAL ANALYSIS 
Statistical analysis were performed using the one-way analysis of variance 
(ANOVA). All tests were completed using Prism (GraphPad, San Diego, 
CA, USA). A p < 0.05 was considered statistically significant. Experiments 





Aim 1: Detection of BRAF mutations in non-malignant 
tissue and analysis of BRAF-mutant activity 
1 NEXT GENERATION SEQUENCING 
Sequencing (NGS) results are summarized in Table 12. 
1.1 THYROID NEOPLASIA MOLECULAR PROFILE  
We analyzed the BRAF exon 15 status of 30 thyroid cancers.  
Ten out of 30 (33.3%) samples were BRAF WT; 5 (50.0%) were PTC-FV, 
while 5 (50.0%) were PTC-CL. 
One sample (PTC-FV) (3.3%) was positive for BRAF p.V600A. 
In 19 out of 30 samples (63.3%) were detected the BRAF p.V600E. Ten out 
of 19 (52.6%) were PTC-CL, 3 (15.8%) were PTC-FV, while 5 (26.3%) 
were PTC-TC. One sample (5.3%) was a sclerosing PTC. 
1.2 NON-MALIGNANT THYROID TISSUE MOLECULAR PROFILE 
We had analyzed 100 non-malignant tissue surrounding the PTCs. 
Ehighty-five sample (85.0%) out of 100 were BRAF WT, while 12 samples 
(12.0%) were positive for a BRAF mutation. Three cases (3.0%) were not 
evaluable.  
Among positive cases, sample 4a (FA-ONC) and sample 12b (HYP) 
















1a ATY WT 
1b HYP WT 
1c NORM WT 
2 
45 F 
Sclerosing PTC p.V600E 
2a ATY WT  
2b ATY WT  




3a PsB  p.V600E 






 p.S607P  
4b HYP p.S607P  
4c NORM WT 
4d HYP WT 
4e NORM WT 




5a ATY WT 
5b NORM WT 




6a ATY WT 
6b PsB p.V600E 
6c NORM WT 
6d HYP WT 
6e ATY WT 




7a ATY p.V600M  
7b NORM WT 
7c NORM WT 




8a PsB p.V600E 
8b NORM WT 
8d NORM p.S607F 
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9a ATY WT 
9b HYP WT 
9c NORM WT 
9d HYP WT 
9e NORM WT 




10a ATY WT 




11a ATY WT 
11b FA WT 








12c NORM WT 
12d ATY NE 
12e ATY WT 




13a ATY WT 
13b ATY WT 
13c NORM WT 
13d ATY p.G593D  
13e HYP WT 




14 a ATY WT 
14 b NORM WT 




15 a ATY WT 
15 b NORM WT 
15 c ATY WT 
16 
58 F 
PTC-TC p.V600E  
16 a  NORM WT 
16 b ATY p.A598T  
16 c ATY WT 
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Case Age Sex Diagnosis Result 
17 
37 F 
PTC-TC p.V600E  
17 a ATY WT 
17 b ATY WT 




18 a NORM WT 
18 b ATY WT 




19 a HYP WT 
19 b HYP WT 




20a NORM WT 
20b HYP WT 
21 
73 F 
PTC-FV p.V600A  
21a NORM WT 
21b ATY WT 




22a NORM WT 




23a NORM WT 




24a ATY NE 
24b ATY WT 




25a NORM WT 
25b ATY WT 
25c HYP WT 




26a NORM WT 




27a NORM WT 
27b FA WT 
27c FA WT 
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28a NORM WT 
28b NORM WT 




29a NORM WT 




30a ATY WT 
30b ATY WT 
30c NORM WT 
Table 12: Next Generation Sequencin results. 
 
 
If only normal thyroid tissues are considered, 34 specimens were analyzed, 
among which 32 (94.1%) were BRAF WT. One out of 34 (2.9%) was not 
evaluable, while 1 (2.9%) was positive for the mutational calling for 
p.S607F. 
Among hyperplastic tissue, 14 (87.5%) out of 16 samples analyzed were 
negative for BRAF mutation, whereas 2 samples (4b and 12b) (12.5%) were 
positive for the presence of BRAF mutation. We observed p.S607P 
substitution in sample 4b, while the sample 12b harbored two mutations, 
p.G593D&p.Q603R. 
When only atypical tissue is considered, 38 specimens were analyzed. 
Thirty-two samples (84.2%) were BRAF WT, whereas 2 (5.3%) were not 
evaluable for BRAF status. Four samples (10.5%) harbored a BRAF 
mutation: sample 7a showed p.V600M, 2 samples (12a and 13d) were BRAF 
p.G593D (Figure 9.B), and sample 6b was positive for p.A598T. 
Six specimens analyzed had psammoma body; 3 (50.0%) were BRAF WT, 
whereas 3 (50.0%) were BRAF p.V600E (Figure 9.A). 
Six FA were analyzed, among wich 2 were FA-ONC. We observed 2 
mutated sample (33.3%): sample 28c (FA) was positive for p.K601E, 
whereas sample 4a (FA-ONC) harboured two mutations, 




Figure 9: A) tissue containing psammoma body BRAF p.V600E (x600); B) atypical 
thyroid tissue BRAF p.G593D positive (x600). 
 
 
Considering only non-malignant tissue sorrounding BRAF p.V600E-positive 
carcinoma, 74 non-malignat specimens were analyzed (Table 13). Eleven 
out of 74 (14.9%) showed a BRAF mutation, while 61 (82.4%) were WT. 
Two samples (2.7%) were not evaluable.  
If only non-malignant tissue surrounding BRAF WT carcinoma were 
considered, we analyzed 26 specimens, among which 24 (92.3%) were WT, 
sample 24a (ATY) (3.8%) was NE and sample 28c (FA) (3.8%) was 
p.K601E (Table 13). 
 
PTC BRAF V600-positive (n=20) 
Non-malignant tissue (n=74) WT (%) MUT (%) NE (%) 
ATY (n=31) 26 (83.9%) 4 (12.9%) 1 (3.2%) 
HYP (n=13) 11 (84.6%) 2 (15.4%) - 
NORM (n=24) 22 (91.7%) 1 (4.2%) 1 (4.2%) 
PsB (n=3) - 3 (100.0%) - 
FA-ONC (n=2) 1 (50.0%) 1 (50.0%) - 
FA (n=1) 1 (100.0%) - - 
    PTC BRAF WT (n=10) 
Non-malignant tissue (n=26) WT (%) MUT (%) NE (%)  
ATY (n=7) 6 (85.7%) - 1 (14.3%) 
HYP (n=3) 3 (100.0%) - - 
NORM (n=10) 10 (100.0%) - - 
PsB (n=3) 3 (100,0%) - - 
FA (n=3) 2 (66,7%) 1 (33,3%) - 




In order to undersand the possible impact of “uncommon” alterations found 
in non-malignant tissue, the tool PolyPhen-2 (Polymorphism Phenotyping 
v2) was used. PolyPhen-2 is an in silico tool that predicts if a mutation 
could be benign (B, score: 0-0.2), possibly damaging (PoD, score: 0.2-0.85) 
or probably damaging (PD, score: 0.85-1.00). All the mutation observed are 
reported in Table 14. 
 
Non-malignant tissue (n) Mutation Reference (PMID) 
PolyPhen 
(score) 
ATY (2), HYP (1) p.G593D  PMID: 19269016 PD (1.000) 
ATY p.A598T  PMID: 22926515 PD (0.871) 
PsB (3), p.V600E PMID: 15035987 PD (0.971) 
*FA-ONC (1) p.V600K PMID: 15035987  PD (1.000) 
ATY (1) p.V600M  PMID: 28783719 PD (0.904) 
FA(1) p.K601E  PMID: 15035987 PoD (0.784) 
HYP (1) p.R603Q   PMID: 23861977 PoD (0.786) 
NORM (1) p.S607F PMID: 23861977 PD (0.998) 
*FA-ONC (1), HYP (1)  p.S607P  PMID: 29176861 B (0.186) 
Table 14: Mutation found in non-malignant tissue surrounding the PTC. “Uncommon” 
BRAF mutations other than p.V600E or p.K601E are present in 9 samples: * one sample, 
FA-ONC harboured two mutations (p.V600K and p.S607P). 
 
 
2 FUNCTIONAL CHARACTERIZATION OF BRAF 
MUTATIONS 
2.1 SELECTION OF MUTANT TO TEST 
To comprehend if the “uncommon” BRAF alteration affect the protein 
activity, we decided to investigate mutation p.G593D, p.A598T, p.S607F, 
p.S607P found in non-malignat tissue surrounding carcinoma.  
We compared BRAF mutant activity to the WT protein and to those with a 




2.2 FUNCTIONAL CHARACTERIZATION  
Through the MAPK pathway, BRAF phosporilates MEK1/2 at serine 217 
and 221, and in turn MEK1/2 phosporilates ERK1/2 at threonine 202 and 
tyrosine 204. We transliently expressed BRAF-G593D, BRAF-A598T, 
BRAF-S607F, BRAF-S607P, BRAF-V600E, BRAF-K601E (both known to 
lead to a higher protein activity) mutant and BRAF-WT in HEK293 cells. 
Forty-eight hours after cell transfection, total proteins were extracted and 
immublotting was carried out. We evatuated the phosphorylation level of 
the protein involved in MAPK pathway (ERK1/2, MEK1/2, BRAF) using 
specific antibodies.  
Densitometric analysis result have been normalized to non-trasfected 
control. 
Phosphorylation level of ERK1/2 was higher in BRAF-V600E (3.8 fold) 
and in BRAF-K601E (2.7 fold) when compared to BRAF-WT (p<0.05). In 
BRAF-G593D and BRAF-A598T ERK1/2 phosphorylation level was lower 
than BRAF-WT, but it was not statistically significant. Phosphorylation 
level of ERK1/2 in BRAF-S607F and BRAF-S607P was similar to BRAF-
WT (Figure 10). 
Phosphorylation levels of MEK1/2 show a similar trend to those of ERK1/2: 
p-MEK1/2 was higher in BRAF-V600E (3.3 fold) and in BRAF-K601E (3.3 
fold) when compared to BRAF-WT, but it was not statistically significant. 
In BRAF-G593D and BRAF-A598T MEK1/2 phosphorylation level was 
lower than BRAF-WT, but it was not statistically significant. 
Phosphorylation level of MEK1/2 in BRAF-S607F and BRAF-S607P was 
similar to BRAF-WT (Figure 10). 
BRAF phosphorylation level in BRAF-G593D, BRAF-A598T, BRAF-
V600E, BRAF-K601E, BRAF-S607F and BRAF-S607P was similar to 





Figure 10: Functional characterization of the BRAF-G593D, BRAF-A598T, BRAF-
S607F, BRAF-S607P. (a) Effect of BRAF mutants on the MAPK signaling  pathway. (b) 
Effect of BRAF mutants on the ERK1/2 phosporylation level. (c) Effect of BRAF mutants 
on the MEK1/2 phosporylation level. (d) Effect of BRAF mutants on the BRAF 
phosporylation level.  
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Aim 2: Design and set up of a gene expression panel. 
3 GENE PANEL RESULTS  
We designed an expression gene panel, which included gene fusions, 
biomarker and thyroid lineage and differentiation, genes involved in 
immune-oncology, genes involved in BRAF-like or RAS-like profiling, 
genes up/down regulated in cancers and proliferation genes.  
DNA and RNA were extracted from 44 FF specimens, RNA was 
retrotranscribed and NGS analysis was carried out. In Figure 11 is reported 
the heatmap, obtained from an unsupervised hierarchical cluster analysis. 
In our panel, we included genes known to be differentially expressed in 
BRAF-positive carcima (BRAF-like signature) or in RAS-positive sample 
(RAS-like signature) (Supplementary Table 1).  
If only BRAF-like signature genes are considered, they show an over-
expression in PTCs-TC, PTCs-CL. Intringuingly, BRAF-like signature 
genes were over-expressed in sample Thy101 (PTC-FV): previous 
molecular analysis showed Thy101 to harbor a mutation in BRAF exon 15. 
BRAF-like genes were down-regulated in non-malignant sample and RAS-
positive sapecimens (PTC-FV, FTC).  Under-expression was observed in 
HCC. In Thy001, Thy182-2 BRAF-positive (ATCs) BRAF-like signature 
genes were not over-expressed. 
Similarly, RAS-like signature genes are over-expressed in RAS-positive 
samples (PTC-FV, FA, FTC). 
We analyzed the expression of 38 genes involved in cell proliferation, such 
as EZH2 or PBK. They result over-expressed in BRAF-positive samples 
including PTCs-TC and PTCs-CL. Differently from BRAF-like signature 
genes, cell proliferation genes were over-expressed ATCs, both BRAF-
positive (Thy001 and Thy182-2) and WT (Thy022).  
The expression of 16 gene involve in thyroid differentiation and biomarker 
for thyroid lineage was analyzed. They result under-regolated in 2 ATC 
BRAF-positive (Thy001 and Thy182-2), in CRC and in MTC. Differently 
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from Thy001 and Thy182-2, Thy022 (ATCs) had the same expression 
pattern of well-differentiated cancers. The expression of biomarker genes 
was over-regulated in normal, hyperplastic and non-malignant tissue 
(including FAs), in FTC BRAF-WT, and in 2 RAS-positive PTCs-FV 
(Thy132 and Thy135). 
In 3 FTCs (Thy085, Thy093, Thy121) were confirmed the PAX8/PPARG 
rearrangement, a marker for follicular patterned carcers. 
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Aim 1: Detection of BRAF mutations in non-malignant 
tissue and analysis of BRAF-mutant activity 
Papillary carcinoma is one the most well characterized cancer, and its 
molecular signature has been deeply investigated [64]. BRAF alterations are 
the most frequent driver mutations in thyroid cancers (40-45%), and the 
~95% are represented the BRAF p.V600E substitution, which mimics the 
protein phosphorylation and results in its the constitutive activation [20, 83, 
107]. To date, there are no information regarding the BRAF molecular 
profile of the non-malignant tissue surrounding the carcinoma. Exploring 
the BRAF molecular signature of tissue surrounding carcinomas could be 
helpful to better understand the thyroid tumorigenesis and the events that 
lead the precursor lesions to evolve, or not, to carcinoma.  
In this study, we explored the BRAF status of 100 areas of non-malignant 
tissue surrounding 10 PTCs BRAF WT and 20 PTCs BRAF-positive. 
Intringuingly, no mutations were found in all tissues but one surrounding 
BRAF-WT carcimonas. In one FA adjacent a BRAF-WT PTC a BRAF 
p.K601E alteration was found. This data is not surprising, in fact, p.K601E 
is known to be associated with follicular-pattern alteration in thyroid 
neoplasms, and it leads to a better outcome than p.V600E positive nodules. 
Specifically, p.K601E mutation has been also previously described in FA 
tumor [114].  
In non-malignat tissue surrounding BRAF positive PTCs we found 
“common” mutations (in codons 600) in areas containing psammoma body 
(p.V600E), oncocytic follicular adenoma (p.V600K) or with an atypical 
architecture (p.V600M).  
The BRAF p.V600E mutation was found in areas containing psammoma 
bodies (PsB). PsB are considered to be the “the ghosts of dead papillae”: 
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they are calcifications resulting from a progressive depositum of calcium on 
dying cells, that confer them a characteristic lamellation [181-183], and 
could arise from nests of tumor cells, as demonstrated by  Johannessen and 
collegues [182]. Finding the BRAF p.V600E mutation in PsB sorrunding 
BRAF-V600E PTC is a further evidence that PsB are a footprint of “dead” 
neoplastic cells.  
The BRAF p.V600K mutation was recently characterized for conferring a 
gain of function to the BRAF protein, resulting in  an  increased kinase 
activity [184]. We found BRAF p.V600K mutation in an oncocytic follicular 
adenoma, arising in a BRAF p.V600E context. Considering that p.V600E 
mutation is a c.1799T>A sobistitution, we supposed that a second point 
mutation occurred in c.1798G>A residue, resulting in c.1798-1799GT>AA 
(p.V600K) alteration. 
The BRAF p.V600M mutation was detected in an area with an atypical 
architecture. It is conceivable that this area was transforming into a 
neoplastic one. In fact,  p.V600M mutation was previously reported to have 
an intermediate kinase activity (lower than BRAF-V600E protein but higher 
than BRAF-WT one) in cell culture [184].  
The following “uncommon” mutations (different from codon 600) were 
found in BRAF exon 15: p.G593D, p.A598T, p.R603Q, p.S607F and 
p.S607P. All of them were previously reported in literature and described in 
different neoplastic tissue. The p.G593D was found in solid cell nest 
hyperplasia associated with BRAF p.V600E papillary thyroid carcinoma 
[185]. 
Both p.R603Q and p.S607F mutations were reported in nevi, in association 
with BRAF-positive melanoma [186], similarly to what we observed in our 
non-malignant area surrounding BRAF-V600E PTC.  
The p.S607P sobsitution was previously described in melanoma [187], 
while the p.A598T were detected in non small cell lung cancers [188] and 
correlates with a decreased activity of BRAF protein [189] . 
All “uncommon” BRAF mutations were observed in non-malignant tissues 
surrounding BRAF-positive PTCs, while they were not detected in tissues 
surrounding the BRAF-WT carcinomas. The higher frequency of this 
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uncommon mutation in non-malignant tissue surrounding BRAF-positive 
PTCs could be due to a genomic  instability. Mitmaker and colleagues 
analyzed for microsatellite instability (MSI) both benign and malignant 
thyroid neoplasms, comparing them to adjacent normal tissue. They 
demonstrated a high rate of MSI both in FTC and PTC (9/14 and 10/16 
sample analyzed, respectively), while benign follicular adenomas showed 
no genomic instability or had a low-MSI [190]. On the contrary, Nikiforov 
and collegues showed that MSI does not seem to contribute to thyroid 
carcinogenesis, expecially in radiation-induced thyroid cancer [191]. Further 
studies are necessary in order to clarify the possible link between MSI and 
presence of “uncommon” mutations in thyroid carcinogenesis. 
 
Through the MAPK pathway, BRAF protein phosporilates MEK1/2 in turn 
MEK1/2 phosporilates ERK1/2. We transiently expressed BRAF-G593D, 
BRAF-A598T, BRAF-V600E, BRAF-K601E, BRAF-S607F and BRAF-
S607P mutant, the phosphorylation levels of ERK1/2, MEK1/2 and BRAF 
proteins were assessed.  
 “Uncommon” BRAF mutants analyzed (BRAF-G593D, BRAF-A598T, 
BRAF-S607F and BRAF-S607P) were not associated with an increased 
MAPK pathway activation. On the contrary, they seemed to have the same 
(or lower) activation of MAPK pathway if compared to BRAF-WT protein. 
In particular, BRAF-G53D and  BRAF-A598T seemed to have a lower 
BRAF activity. 
We compared the activity of BRAF mutant found in non-malignant tissue 
(BRAF-G593D, BRAF-A598T, BRAF-S607F and BRAF-S607P) to the one 
of BRAF-WT, BRAF-V600E and BRAF-K601E proteins. As expected, we 
observed higher level of activation of MAPK pathway in BRAF-V600E and 
BRAF-K601E when compared to WT. In fact, it is well known that these 
alterations lead to a constitutive activation of BRAF protein [102]. 
BRAF phosphorylation level of BRAF-G593D, BRAF-A598T, BRAF-
V600E, BRAF-K601E, BRAF-S607F and BRAF-S607P were similar to 
BRAF-WT. As expected, both “common” and “uncommon” BRAF 
mutations do not lead to an increase phosphorylation level of the protein. In 
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fact, activating mutations, such as p.V600E and p.K601E, mimic the 
phosphorilation of the activation segment, but they do not increase the 
BRAF affinity for the phosphate [102]. 
BRAF p.G593D and p.A598T mutants showed a lower MAPK pathway 
activation when compared to BRAF WT. These results are comparable with 
those obtained by Rebocho and colleagues [189]. Alterations in histological 
architecture in tissue harbouring these mutations could be due to other 
defects in genes involved in cell proliferation, such as RAS or 
PI3K/AKT/PTEN pathway. Exploring the molecular signature of oncogenes 
different from BRAF, such as RAS, could clarify the development of 
histologically begnin thyroid lesions. 
 
 
Aim 2: Design and set up of a gene expression panel. 
The combination of cytology analysis and molecular testing have improved 
the pre-operative evaluation of thyroid lesions. However, a lot of pre-
operative samples are diagnosed as “indeterminate” (Thy-3 according to 
cytological classification of thyroid samples). Understanding the molecular 
expression assessment in thyroid lesions could be useful for the 
establishment of a correct surgical approach, as well as treatment decision 
and prognostic information. 
The expression panel was designed to detect gene fusion and gene 
expression recurrently altered in thyroid cancers and with potential for 
diagnostic and clinical relevance. We verified that our panel is able to 
clusterize sample in three main groups: i) non-malignant tissue; ii) 
malignant tissue; iii) non-follicular thyroid cell derived cancers. 
We analyzed the expression of genes involve in thyroid differentiation and 
lineage, observing an up-regulation in non-malignant samples, including 
normal and hyperplastic tissue and follicular adenoma. A down-regolation 
was observed in two ATCs (Thy001 and Thy182-2), in CRC and in MTC. 
The expression level of these gene could be very useful for clusterization in 
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non-malignant versus malignant tissue. Considering non-malignant tissue 
cluster, we observed three outlier samples: in fact, Thy112 (FTC), Thy040 
and Thy137 (both PTC-FV) had the same expression pattern of non-
malignant specimens. On the contrary, a RAS-positive FA (Thy024) was 
clusterized as malignant. Differently from Thy001 and Thy182-2, Thy022 
(ATC) had the same expression pattern of well-differentiated cancers. The 
expression level analysis of these genes is able to well clusterized non-
malignat sample, undifferentiated carcinoma, and non-follicular thyroid 
cells derived cancer from follicura cells derived malignant neoplasia.  
In our panel, we included genes known to be differentially expressed in 
BRAF-positive carcinoma (BRAF-like signature) or in RAS-positive sample 
(RAS-like signature). When only malignant tissue is considered, our panel 
is able to clusterize sample in to follicular patterned cancer and papillary 
patterned cancer. Intriguingly, Thy101 (PTC-FV BRAF-positive) was 
clusterized as a BRAF-like sample, even if it had a follicular pattern 
histological architecture.  
In our panel, primers were design to detect known recurrent gene fusions 
(through primers annealing to thewell-known breakpoint) as well as fusions 
of novel isoforms of ALK, BRAF, FGFR2, NTRK1, NTRK3, PPARG, RAF1, 
ROS1 and  THADA genes, through 3′/5′ expression imbalance. Furthermore, 
we confirmed the PAX8/PPARG rearrangement in 3 samples. 
Further analyses are needed for additional validation and assessment of our 
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Supplementary Table 1: Genes included in our RNA-based expression 
pannel 
Gene Breakpoints Annotation Detail 
AGK-/-BRAF 1 PTC Gene Fusion 
AKAP13-/-RET 1 PTC Gene Fusion 
AKAP9-/-BRAF 2 PTC Gene Fusion 
CCDC6-/-RET 3 PTC Gene Fusion 
CREB3L2-/-PPARG 1 FC Gene Fusion 
EML4-/-ALK 36 PTC Gene Fusion 
ERC1-/-RET 7 PTC Gene Fusion 
ETV6-/-NTRK3 2 PTC Gene Fusion 
FGFR2-/-OFD1 1 PTC Gene Fusion 
GOLGA5_PTC5-/-RET 1 PTC Gene Fusion 
HOOK3-/-RET 1 PTC Gene Fusion 
KTN1-/-RET 1 PTC Gene Fusion 
MACF1-/-BRAF 1 PTC Gene Fusion 
MKRN1-/-BRAF 1 PTC Gene Fusion 
70 
 
NTRK1-/-TFG 6 PTC Gene Fusion 
NTRK3-/-ETV6 1 PTC Gene Fusion 
PAX8-/-PPARG 5 FC Gene Fusion 
PCM1-/-RET 2 PTC Gene Fusion 
PRKAR1A-/-RET 2 PTC Gene Fusion 
RET-/-TRIM33 1 PTC Gene Fusion 
SND1-/-BRAF 1 PTC Gene Fusion 
SQSTM1-/-NTRK1 1 PTC Gene Fusion 
SSBP2-/-NTRK1 1 PTC Gene Fusion 
TBL1XR1-/-RET 2 PTC Gene Fusion 
TFG-/-ALK 3 PTC Gene Fusion 
TPM3-/-NTRK1 1 PTC Gene Fusion 
TPR-/-NTRK1 1 PTC Gene Fusion 
TRIM24-/-RET 3 PTC Gene Fusion 
TRIM27-/-RET 2 PTC Gene Fusion 
71 
 
TRIM33-/-RET 2 PTC Gene Fusion 
CITED1 - Biomarker  Gene Expression 
KLK10 - Biomarker  Gene Expression 
FHL1 - BRAF down  Gene Expression 
HLF - BRAF down  Gene Expression 
IRS1 - BRAF down  Gene Expression 
MMP15 - BRAF down  Gene Expression 
TFF3 - BRAF down  Gene Expression 
ANXA1 - BRAF signature  Gene Expression 
DUSP5 - BRAF signature  Gene Expression 
PROS1 - BRAF signature  Gene Expression 
SDC4 - BRAF signature  Gene Expression 
SLC35F2 - BRAF signature  Gene Expression 
SYT12 - BRAF signature  Gene Expression 
ARNTL - 
BRAF signature 












DCSTAMP - BRAF up  Gene Expression 
ERBB3 - BRAF up  Gene Expression 
GATA3 - BRAF up  Gene Expression 
GNLY - BRAF up  Gene Expression 
ITGB6 - BRAF up  Gene Expression 
TMPRSS6 - BRAF up  Gene Expression 
TPD52L1 - BRAF up  Gene Expression 
SFTPB - BRAF/RET up  Gene Expression 
IPCEF1 - Cancer down  Gene Expression 
PAPSS2 - Cancer down  Gene Expression 
RGS16 - Cancer down  Gene Expression 
ENTPD1 - Cancer up  Gene Expression 
LRP4 - Cancer up  Gene Expression 
73 
 
ALK - Expressed fusion Gene Expression 
BRAF - Expressed fusion Gene Expression 
FGFR2 - Expressed fusion Gene Expression 
NTRK1 - Expressed fusion Gene Expression 
NTRK3 - Expressed fusion Gene Expression 
PPARG - Expressed fusion Gene Expression 
RAF1 - Expressed fusion Gene Expression 
ROS1 - Expressed fusion Gene Expression 
THADA - Expressed fusion Gene Expression 
AAMP - Housekeeping Gene Expression 
AAR2 - Housekeeping Gene Expression 
ACTB - Housekeeping Gene Expression 
ARF1 - Housekeeping Gene Expression 
ATP5E - Housekeeping Gene Expression 
CLTC - Housekeeping Gene Expression 
74 
 
DEDD - Housekeeping Gene Expression 
GAPDH - Housekeeping Gene Expression 
GPKOW - Housekeeping Gene Expression 
GPS1 - Housekeeping Gene Expression 
GPX1 - Housekeeping Gene Expression 
HMBS - Housekeeping Gene Expression 
MMADHC - Housekeeping Gene Expression 
MRFAP1 - Housekeeping Gene Expression 
MRPS9 - Housekeeping Gene Expression 
PGK1 - Housekeeping Gene Expression 
PPP2CA - Housekeeping Gene Expression 
PSMA1 - Housekeeping Gene Expression 
PSMC1 - Housekeeping Gene Expression 
RPL13A - Housekeeping Gene Expression 
RPL37 - Housekeeping Gene Expression 
75 
 
RPL8 - Housekeeping Gene Expression 
SDHA - Housekeeping Gene Expression 
SLC25A3 - Housekeeping Gene Expression 
TXNL1 - Housekeeping Gene Expression 
UBA52 - Housekeeping Gene Expression 
ZC3HC1 - Housekeeping Gene Expression 
CD274 - Immuno-oncology Gene Expression 
CD8A - Immuno-oncology Gene Expression 
CD8B - Immuno-oncology Gene Expression 
CTLA4 - Immuno-oncology Gene Expression 
CXCL10 - Immuno-oncology Gene Expression 
CXCL9 - Immuno-oncology Gene Expression 
FOXP3 - Immuno-oncology Gene Expression 
GZMA - Immuno-oncology Gene Expression 
HAVCR2 - Immuno-oncology Gene Expression 
76 
 
IDO1 - Immuno-oncology Gene Expression 
LAG3 - Immuno-oncology Gene Expression 
PDCD1 - Immuno-oncology Gene Expression 
PDCD1LG2 - Immuno-oncology Gene Expression 
PRF1 - Immuno-oncology Gene Expression 
TIGIT - Immuno-oncology Gene Expression 
TMEM173 - Immuno-oncology Gene Expression 
TNFRSF4 - Immuno-oncology Gene Expression 
TNFRSF9 - Immuno-oncology Gene Expression 
CALCA - Lineage Gene Expression 
CEACAM5 - Lineage Gene Expression 
CGA - Lineage Gene Expression 
PAX8 - Lineage Gene Expression 
TP63 - Lineage Gene Expression 
TTF1 - Lineage Gene Expression 
77 
 
ASF1B - Proliferation Gene Expression 
ASPM - Proliferation Gene Expression 
AURKA - Proliferation Gene Expression 
BIRC5 - Proliferation Gene Expression 
BUB1B - Proliferation Gene Expression 
CDC20 - Proliferation Gene Expression 
CDCA3 - Proliferation Gene Expression 
CDCA8 - Proliferation Gene Expression 
CDK1 - Proliferation Gene Expression 
CDK4 - Proliferation Gene Expression 
CDKN3 - Proliferation Gene Expression 
CENPF - Proliferation Gene Expression 
CENPM - Proliferation Gene Expression 
CEP55 - Proliferation Gene Expression 
DLGAP5 - Proliferation Gene Expression 
78 
 
DTL - Proliferation Gene Expression 
EZH2 - Proliferation Gene Expression 
FOXM1 - Proliferation Gene Expression 
KIAA0101 - Proliferation Gene Expression 
KIF11 - Proliferation Gene Expression 
KIF20A - Proliferation Gene Expression 
MCM10 - Proliferation Gene Expression 
MCM4 - Proliferation Gene Expression 
MKI67 - Proliferation Gene Expression 
NUSAP1 - Proliferation Gene Expression 
ORC6 - Proliferation Gene Expression 
PBK - Proliferation Gene Expression 
PLK1 - Proliferation Gene Expression 
PRC1 - Proliferation Gene Expression 
PTTG1 - Proliferation Gene Expression 
79 
 
RAD51 - Proliferation Gene Expression 
RAD54L - Proliferation Gene Expression 
RRM2 - Proliferation Gene Expression 
SKA1 - Proliferation Gene Expression 
TK1 - Proliferation Gene Expression 
TOP2A - Proliferation Gene Expression 
TPX2 - Proliferation Gene Expression 
UBE2C - Proliferation Gene Expression 
CFH - RAS down  Gene Expression 
S100A10 - RAS down  Gene Expression 
ANKRD46 - RAS signature  Gene Expression 
CYB561 - RAS signature  Gene Expression 
GNA14 - RAS signature  Gene Expression 
KATNAL2 - RAS signature  Gene Expression 
LGI3 - RAS signature  Gene Expression 
80 
 
MLEC - RAS signature  Gene Expression 
SFTPC - RAS signature  Gene Expression 
HGD - 
RAS signature 
















RAS up  
Gene Expression 
PIWIL1 - RAS up  Gene Expression 
SNRNP25 - RAS up  Gene Expression 
MBNL2 - RET down  Gene Expression 
MYL4 - RET up  Gene Expression 
SORBS1 - RET up  Gene Expression 
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